ADMA Biologics, Inc. (ADMA) Stock Analysis

87.0/100
Strong Buy ✓ Halal Healthcare
Price $13.82
Market Cap $3.03B
52-Week Change -12.87%

Is ADMA a good investment?

ADMA Biologics, Inc. (ADMA) has a Plutrex AI rating of 87.0/100 as of November 05, 2026, indicating a Strong Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Exceptional profitability in a loss-heavy industry: Operating margin +42.2% vs. industry average -108.6%, net margin 33.0% vs. industry -0.02%, ROE 41.9% vs. industry -3.15% — ADMA is a true profit machine in a sector where most companies burn cash. FCF of $116.5M validates earnings quality.. Main concern: Revenue growth of only 2.0% is the Achilles' heel — earnings growing at 22.2% while revenues grow at 2.0% requires perpetual margin expansion, which mathematically has limits. If margins plateau, the EPS growth projection collapses, and the low P/E would suddenly look fair rather than cheap. Top-line acceleration to at least 8-12% is needed to validate the full bull case..

Investment Summary

ADMA Biologics is a rare specimen in the biotech universe: a genuinely profitable, cash-generating specialty biologics company trading at a dramatic discount to both its intrinsic value and industry peers. At $13.60, ADMA sports a P/E of 14.88x against a 22.2% five-year forward EPS CAGR — producing a PEG ratio of 0.67, meaning investors pay just 67 cents for every dollar of projected growth. The industry average PEG is 2.27x, making ADMA 70.5% cheaper on a growth-adjusted basis than the average profitable biotech. Net margin of 33.0%, operating margin of 42.2%, and ROE of 41.9% are elite-tier metrics that the vast majority of the 136-company biotech peer group cannot approach (industry average operating margin: -108.6%). Recent Q3 results beat both earnings and revenue estimates ('Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates'), and peer-reviewed publication of optimized IVIG manufacturing data ('ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized Proprietary IVIG Manufacturing Process') confirms the gross margin expansion story is scientifically validated — a 1,450 basis point gross margin improvement is extraordinary. The SG-001 Pre-IND regulatory progress adds pipeline optionality. The primary risk is the tepid 2.0% revenue growth rate, which creates a sustainability question around the 22.2% EPS growth projection — but the manufacturing yield improvements and product mix shift toward higher-margin ASCENIV provide a credible near-term bridge.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
82/100
Growth Potential
72/100
Valuation
92/100
Profitability
97/100
Debt Management
78/100
Analyst Sentiment
65/100
Technical Momentum
70/100
Insider Confidence
68/100
News Sentiment
90/100

Fundamental Analysis

ADMA's fundamentals are exceptional across nearly all dimensions. Profitability: Gross margin 64.7% (below biotech industry average of 80.2% due to plasma manufacturing costs, but expanding rapidly with 1,450bps improvement), operating margin 42.2% (vs. industry average -108.6% — a 150.8pp absolute advantage), net margin 33.0% (vs. industry -0.02%), ROE 41.9% (vs. industry -3.15%). These are Buffett-quality economics: elite capital efficiency with real cash earnings. Financial Health: D/E of 0.49 is 2.1x the industry average of 0.23, but context matters — ADMA has $136M cash and generates $116.5M FCF annually, making the debt trivially serviceable. FCF conversion from net income is high, confirming earnings quality. Growth: The tension between 2.0% revenue growth and 22.2% forward EPS CAGR is the central analytical challenge. Historical EPS growth of 32.2% YoY (decelerating to 22.2% projected) is driven by margin expansion and operating leverage, not top-line volume. The 1,450bps gross margin improvement from optimized manufacturing provides a credible mechanism for continued margin-driven earnings growth. Next-year EPS growth of 18.4% is solid. Valuation: P/E 14.88x vs. industry 27.67x (46.2% discount), PEG 0.67 vs. industry 2.27 (70.5% discount), P/B 5.79 (justified by 41.9% ROE). Fair value P/E at PEG=1.0 implies ~$20-$22 intrinsic value, representing 47-62% upside from $13.60.

News Sentiment

ADMA Biologics is quietly executing one of the most compelling turnaround stories in biotech — and Wall Street is only just starting to notice. The Maryland-based plasma biologics company delivered a knockout third quarter, beating both earnings and revenue estimates in results that validated what company insiders have been saying for months: their manufacturing improvements are translating directly to the bottom line. The headline numbers tell an impressive story. ADMA's proprietary IVIG manufacturing process — the backbone of its high-margin ASCENIV product — just received the ultimate validation: a peer-reviewed publication confirming the company's optimized process delivers dramatically better yields. That's not marketing speak; that's science confirming that ADMA's cost improvements are real and reproducible, translating to a stunning 1,450 basis point improvement in gross margins. Beyond the core business, ADMA disclosed encouraging feedback from regulators on SG-001, its next pipeline candidate, in a Pre-IND meeting — suggesting the company isn't a one-product wonder but is building toward a broader biologics franchise. For everyday investors, the picture is straightforward: a profitable, growing specialty drug company trading at bargain-basement valuations (P/E of under 15x) with momentum in both its operations and its pipeline, in an industry where most competitors are losing money. The question isn't whether ADMA is undervalued — it clearly is. The question is what will finally make the market notice.

Risk Assessment

PRIMARY RISK: Revenue growth stagnation at 2.0% creating a ceiling on earnings growth once gross margin expansion opportunities are exhausted. The manufacturing optimization that drove the 1,450bps gross margin improvement appears mostly captured — further gains may be incremental. Mitigation: Monitor quarterly revenue growth for signs of acceleration; a move above 8-10% would validate the bull case. SECONDARY RISK: Concentration in a single commercial product (ASCENIV/IVIG) with plasma supply chain dependencies — input cost spikes or supply disruptions could compress the gross margin expansion narrative. Mitigation: SG-001 pipeline progress reduces long-term concentration risk. TERTIARY RISK: Limited institutional coverage and no analyst price target means valuation re-rating may be slow; stock could remain cheap for 12-18+ months even with strong fundamentals. Mitigation: Position sizing accounts for this — 4.5% position balances conviction with time-horizon uncertainty. STOP LOSS rationale: $11.40 represents approximately 16% below entry, below key support and would indicate fundamental deterioration rather than normal volatility. At PEG of 0.67 and demonstrated profitability, a stop below $11.40 reflects genuine business deterioration rather than market noise.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is ADMA a halal stock?

Yes, ADMA Biologics, Inc. (ADMA) is halal-compliant per AAOIFI standards as of the latest quarterly review.

What is Plutrex's AI rating for ADMA?

ADMA Biologics, Inc. (ADMA) has a Plutrex AI rating of 87.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is ADMA a good investment?

According to Plutrex AI, ADMA has a Strong Buy rating (87.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in ADMA?

US stocks like ADMA can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in ADMA?

Plutrex AI identifies the main risks for ADMA by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about ADMA

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open ADMA in ElBarake